Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.
about
Rodent models of genetic contributions to motivation to abuse alcoholLong term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.Factors affecting willingness to provide buprenorphine treatment.Study results from the Clinical Trials Network's first 10 years: where do they lead?Diffusion of contingency management and attitudes regarding its effectiveness and acceptability.Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizationsHow serious of a problem is staff turnover in substance abuse treatment? A longitudinal study of actual turnover.The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment.Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practiceTiming of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clustersPhysicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.Financial factors and the implementation of medications for treating opioid use disorders.Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Availability of addiction medications in private health plans.Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.Adoption of medications in substance abuse treatment: priorities and strategies of single state authoritiesClinical supervision, emotional exhaustion, and turnover intention: a study of substance abuse treatment counselors in the Clinical Trials Network of the National Institute on Drug Abuse.Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatmentBuprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.The National Drug Abuse Treatment Clinical Trials Network: forging a partnership between research knowledge and community practice.Research participation and turnover intention: An exploratory analysis of substance abuse counselors.The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.Integration of Care in the Implementation of the Affordable Care Act: Changes in Treatment Services in a National Sample of Centers Treating Substance Use Disorders.Description of a Comprehensive Addiction Rotation at a Psychiatry Residency Program.A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies
P2860
Q33359262-5FA0C897-9441-40D9-8499-E5A04D0057E1Q33582068-AD99BCF6-B9E8-40B4-900F-13427296974BQ33803543-15C3AB10-4042-420D-9443-4B97F38AAFA2Q33836333-7D448F78-10E6-41C2-BC63-22FCCFE81431Q34018862-EC74E7F8-AEE6-46D0-8DA9-D1558F90BEBEQ34076189-B95DFF83-6B3B-4B91-84BD-53A3BA3F1564Q34111054-CF2C3996-593D-458E-8729-28D1B21CEA8EQ34117686-F30C33B1-6ECD-4EF6-92DF-1E9FE67D0841Q34363688-07461099-8A85-4621-8057-B442CD0F1FC0Q34389080-A57DE45D-E674-411C-A624-DA06B90DD20AQ35577449-5740A4D6-420F-4232-82B4-A42FD0714B38Q35792939-F29386CA-CB31-4F5C-8A2A-C2013090FA07Q35937004-CD6748B8-1A55-400D-AFB0-BC670C28E2CFQ36381418-4A4E1A91-B607-473E-81D5-1CE31A8BFBBFQ36394429-14E7ECE2-37D7-4AF7-BC54-218F397C1E79Q36594523-B7F558F3-C7D4-42F8-8690-E8A0EE4C3C04Q36627877-956EF0F7-49F0-48FA-B18E-C7816556F887Q36806539-2B30924B-A8B2-412B-AD05-BCC5F805ED72Q37087541-698BAD78-0E42-41F4-8E26-768D5A9AA3E8Q37272343-9EAA6D38-F643-4EB1-9EEC-F2CC83C240FFQ37352259-90F916A8-B441-4993-942D-3EBD01E48AD5Q37355266-C0C4B62A-7C45-412C-91AE-B7027A129A7CQ37394190-1285A7F9-04E1-4F94-B818-8F0D2F4106C9Q37729027-276FF0BE-8DA3-41FC-B5E5-7165334CA7F3Q38871371-F19C1BF2-5686-4817-99D7-EF2AE3A08AE9Q48305418-27A2A30F-9B78-48CA-B3F9-F36055A12E7CQ58786012-E17ACF62-31BD-47BC-AD8F-4DAD58762FDF
P2860
Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Challenges in the adoption of ...... on to alcohol and other drugs.
@ast
Challenges in the adoption of ...... on to alcohol and other drugs.
@en
type
label
Challenges in the adoption of ...... on to alcohol and other drugs.
@ast
Challenges in the adoption of ...... on to alcohol and other drugs.
@en
prefLabel
Challenges in the adoption of ...... on to alcohol and other drugs.
@ast
Challenges in the adoption of ...... on to alcohol and other drugs.
@en
P1476
Challenges in the adoption of ...... on to alcohol and other drugs.
@en
P2093
Andrew J Saxon
Dennis McCarty
P304
P356
10.1016/J.PHARMTHERA.2005.06.014
P577
2005-10-01T00:00:00Z